Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brenda Sandburg

New York, NY
Brenda Sandburg is a senior writer who covers legal issues and FDA regulatory policy, with a particular focus on patents, biosimilars, and government investigations. She spent 10 years writing for legal publications between stints at The Pink Sheet and blends these experiences to provide in-depth analysis of events. An aspiring photographer, she enjoys taking photos to accompany news stories.

Latest From Brenda Sandburg

Small Biotech Companies Could Get Faster USPTO Review Of COVID-19 Patent Applications

Pilot program aims to examine applications for COVID-19 products subject to approval by FDA within 6 to 12 months; the prioritized examination is available solely for small entities and would save them $2,000.

Coronavirus COVID-19 Intellectual Property

Woodcock, Marks Recusals From COVID-19 Product Reviews 'Protect FDA's Reputation'

FDA experts say there is deep bench in CDER and CBER to tackle review questions while directors Janet Woodcock and Peter Marks help lead Operation Warp Speed; regulatory community is 'reassured' they will oversee advancement of COVID-19 therapeutics and vaccines.

Coronavirus COVID-19 FDA

Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In

As World Health Assembly prepares resolution for voluntary pooling and licensing, Novartis global head of IP Corey Salsberg discusses how intellectual property is advancing development of therapeutics and vaccines and the benefits of voluntary rather than compulsory licensing; 

Coronavirus COVID-19 Intellectual Property

Trump’s ‘Warp Speed’ Initiative Could Fund 3 to 5 Large-Scale COVID Vaccine Trials

FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.

Vaccines Clinical Trials

Can GSK Veteran Moncef Slaoui Get COVID-19 Vaccine Development To Warp Speed?

President Trump's Operation Warp Speed initiative aims to have a COVID-19 vaccine available by the end of the year; Slaoui, who helped get the first cervical cancer vaccine to market and win European approval of the first malaria vaccine while at GlaxoSmithKline, is tasked with coordinating the government's contributions to coronavirus vaccine effort and achieving what would be twin scientific and manufacturing miracles. 

Coronavirus COVID-19 Vaccines

Apotex Execs Avoid Criminal Charges Under DOJ Deferred Prosecution Agreement

While former Sandoz and Heritage execs were charged in the government's generic price-fixing probe, Apotex and its employees will apparently escape such fate if they abide by the terms of DOJ agreement; company admits to fixing price of pravastatin and agrees to pay $24.1m criminal penalty.

Generic Drugs Legal Issues
See All